| Melodi Javid Whitley, MD | |
|
2301 Erwin Rd, Durham, NC 27705-4699 | |
| (919) 684-8111 | |
| Not Available |
| Full Name | Melodi Javid Whitley |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 7 Years |
| Location | 2301 Erwin Rd, Durham, North Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447782263 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 2022-02336 (North Carolina) | Primary |
| 390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Duke University Hospital | Durham, NC | Hospital |
| Duke Health Raleigh Hospital | Raleigh, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Duke Health Integrated Practice Inc | 8325412737 | 2551 |
News Archive
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the U.S. Food and Drug Administration (FDA) has granted marketing approval for METOZOLV™ ODT (metoclopramide HCl) 5mg and 10mg orally disintegrating tablets. METOZOLV ODT is indicated for the relief of symptoms in adults associated with acute and recurrent diabetic gastroparesis and for the treatment of short-term therapy (4-12 weeks) for adults with symptomatic documented gastroesophageal reflux disease (GERD) who fail to respond to conventional therapy1.
The microbiology team of David Berry, Alexander Loy and Michael Wagner from the Faculty of Life Sciences, in collaboration with scientists at the Max F. Perutz Laboratories and with the help of NanoSIMS technology, has for the first time succeeded in directly observing microorganisms feeding on the intestinal mucosa.
Two new clinical trials are examining the safety and acceptability of antiretroviral medicines administered via injection as a means of protecting against HIV infection. The studies are being funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and conducted by the NIAID-funded HIV Prevention Trials Network (HPTN).
Sanofi US and the Alliance for a Healthier Generation, a non-profit organization founded by the American Heart Association and the William J. Clinton Foundation, today announced a new model for the private sector to combat childhood obesity.
Salix Pharmaceuticals, Ltd. today reported that the Gastrointestinal Drugs Advisory Committee of the FDA has recommended by a vote of 14 to 4 in favor of the approval of XIFAXAN® (rifaximin) Tablets, 550 mg for the maintenance of remission of hepatic encephalopathy (HE).
› Verified 4 days ago
| Entity Name | Private Diagnostic Clinic Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457389033 PECOS PAC ID: 1355254368 Enrollment ID: O20031204000577 |
News Archive
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the U.S. Food and Drug Administration (FDA) has granted marketing approval for METOZOLV™ ODT (metoclopramide HCl) 5mg and 10mg orally disintegrating tablets. METOZOLV ODT is indicated for the relief of symptoms in adults associated with acute and recurrent diabetic gastroparesis and for the treatment of short-term therapy (4-12 weeks) for adults with symptomatic documented gastroesophageal reflux disease (GERD) who fail to respond to conventional therapy1.
The microbiology team of David Berry, Alexander Loy and Michael Wagner from the Faculty of Life Sciences, in collaboration with scientists at the Max F. Perutz Laboratories and with the help of NanoSIMS technology, has for the first time succeeded in directly observing microorganisms feeding on the intestinal mucosa.
Two new clinical trials are examining the safety and acceptability of antiretroviral medicines administered via injection as a means of protecting against HIV infection. The studies are being funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and conducted by the NIAID-funded HIV Prevention Trials Network (HPTN).
Sanofi US and the Alliance for a Healthier Generation, a non-profit organization founded by the American Heart Association and the William J. Clinton Foundation, today announced a new model for the private sector to combat childhood obesity.
Salix Pharmaceuticals, Ltd. today reported that the Gastrointestinal Drugs Advisory Committee of the FDA has recommended by a vote of 14 to 4 in favor of the approval of XIFAXAN® (rifaximin) Tablets, 550 mg for the maintenance of remission of hepatic encephalopathy (HE).
› Verified 4 days ago
| Entity Name | Duke Health Integrated Practice Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205553369 PECOS PAC ID: 8325412737 Enrollment ID: O20230327002247 |
News Archive
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the U.S. Food and Drug Administration (FDA) has granted marketing approval for METOZOLV™ ODT (metoclopramide HCl) 5mg and 10mg orally disintegrating tablets. METOZOLV ODT is indicated for the relief of symptoms in adults associated with acute and recurrent diabetic gastroparesis and for the treatment of short-term therapy (4-12 weeks) for adults with symptomatic documented gastroesophageal reflux disease (GERD) who fail to respond to conventional therapy1.
The microbiology team of David Berry, Alexander Loy and Michael Wagner from the Faculty of Life Sciences, in collaboration with scientists at the Max F. Perutz Laboratories and with the help of NanoSIMS technology, has for the first time succeeded in directly observing microorganisms feeding on the intestinal mucosa.
Two new clinical trials are examining the safety and acceptability of antiretroviral medicines administered via injection as a means of protecting against HIV infection. The studies are being funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and conducted by the NIAID-funded HIV Prevention Trials Network (HPTN).
Sanofi US and the Alliance for a Healthier Generation, a non-profit organization founded by the American Heart Association and the William J. Clinton Foundation, today announced a new model for the private sector to combat childhood obesity.
Salix Pharmaceuticals, Ltd. today reported that the Gastrointestinal Drugs Advisory Committee of the FDA has recommended by a vote of 14 to 4 in favor of the approval of XIFAXAN® (rifaximin) Tablets, 550 mg for the maintenance of remission of hepatic encephalopathy (HE).
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Melodi Javid Whitley, MD 2301 Erwin Rd, Durham, NC 27705-4699 Ph: (919) 684-8111 | Melodi Javid Whitley, MD 2301 Erwin Rd, Durham, NC 27705-4699 Ph: (919) 684-8111 |
News Archive
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the U.S. Food and Drug Administration (FDA) has granted marketing approval for METOZOLV™ ODT (metoclopramide HCl) 5mg and 10mg orally disintegrating tablets. METOZOLV ODT is indicated for the relief of symptoms in adults associated with acute and recurrent diabetic gastroparesis and for the treatment of short-term therapy (4-12 weeks) for adults with symptomatic documented gastroesophageal reflux disease (GERD) who fail to respond to conventional therapy1.
The microbiology team of David Berry, Alexander Loy and Michael Wagner from the Faculty of Life Sciences, in collaboration with scientists at the Max F. Perutz Laboratories and with the help of NanoSIMS technology, has for the first time succeeded in directly observing microorganisms feeding on the intestinal mucosa.
Two new clinical trials are examining the safety and acceptability of antiretroviral medicines administered via injection as a means of protecting against HIV infection. The studies are being funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and conducted by the NIAID-funded HIV Prevention Trials Network (HPTN).
Sanofi US and the Alliance for a Healthier Generation, a non-profit organization founded by the American Heart Association and the William J. Clinton Foundation, today announced a new model for the private sector to combat childhood obesity.
Salix Pharmaceuticals, Ltd. today reported that the Gastrointestinal Drugs Advisory Committee of the FDA has recommended by a vote of 14 to 4 in favor of the approval of XIFAXAN® (rifaximin) Tablets, 550 mg for the maintenance of remission of hepatic encephalopathy (HE).
› Verified 4 days ago
John F Carr, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 4012 Colville Rd, Durham, NC 27707 Phone: 919-489-1826 | |
Dr. John Carroll Murray, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: Box 2907 Div Derm Duke Univ Med Center, Durham, NC 27710 Phone: 919-684-2393 Fax: 919-684-6505 | |
Brooke A Jackson, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 245 E Nc Highway 54, Suite 202, Durham, NC 27713 Phone: 919-294-9440 Fax: 919-237-3899 | |
Dr. Michelle Bernadette Pavlis, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 5324 Mcfarland Rd, Suite 210, Durham, NC 27707 Phone: 919-684-8111 | |
Dr. Sabrina Michelle Shearer, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 5324 Mcfarland Rd, Durham, NC 27707 Phone: 919-401-3376 Fax: 919-401-0378 | |
Dr. Lawrence Etter, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3008 Pickett Rd, Durham, NC 27705 Phone: 919-286-7903 Fax: 919-286-7151 | |
Elizabeth L. West, P.A. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2100 Erwin Rd, Durham, NC 27710 Phone: 919-684-8111 |